Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: Insights into organ toxicities

Adeno-associated virus (AAV)-based gene transfer has brought transformative therapeutic benefits to patients with otherwise untreatable genetic diseases. However, treatment-related organ toxicities, particularly for high doses, remain a safety concern in the clinic with some translatability in preclinical species. In the present study, we conducted an RNA sequencing (RNA-seq) analysis in non-human primates administered intrathecally with scAAV9-CBA-GFP, empty viral capsid particles, or a "Promoterless" vector. This analysis revealed a broad and long-lasting (4 weeks after dosing) transcriptional impact of the viral transduction/transgene expression on tissues. Liver and dorsal root ganglia (DRGs), known to be the primary sites of toxicity induced by AAV9, had the highest viral load and the most significant transcriptional changes. Our analysis revealed that most of the differentially expressed genes were upregulated and common gene signatures belonged to immune pathways (innate and adaptive), demonstrating a persistent low-grade immune response up to 4 weeks post-dosing. Interestingly and across all tissues considered, the impact of empty capsids or of the Promoterless vector was minimal, suggesting that the presence of the capsid and a productive viral genome causes the observed changes. This study provides unique insights into the transcriptional responses to AAV9 in key tissues primarily exposed by the vector.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Methods & Clinical Development
Published
2025-10-17
DOI
https://doi.org/10.1016/j.omtm.2025.101617
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: Insights into organ toxicities

Philippe Couttet, Eloïse Hudry, Karine Bigot, John T. Singer et al.
Molecular Therapy — Methods & Clinical Development
Virus-based gene therapy research
article

Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: Insights into organ toxicities

Philippe Couttet, Eloïse Hudry, Karine Bigot, John T. Singer, Tony del Rio, Vera M. Ruda, Fumiaki Aihara, Megumi Onishi‐Seebacher, Keith Mansfield, Matthew Mardo
article en

Abstract

Adeno-associated virus (AAV)-based gene transfer has brought transformative therapeutic benefits to patients with otherwise untreatable genetic diseases. However, treatment-related organ toxicities, particularly for high doses, remain a safety concern in the clinic with some translatability in preclinical species. In the present study, we conducted an RNA sequencing (RNA-seq) analysis in non-human primates administered intrathecally with scAAV9-CBA-GFP, empty viral capsid particles, or a "Promoterless" vector. This analysis revealed a broad and long-lasting (4 weeks after dosing) transcriptional impact of the viral transduction/transgene expression on tissues. Liver and dorsal root ganglia (DRGs), known to be the primary sites of toxicity induced by AAV9, had the highest viral load and the most significant transcriptional changes. Our analysis revealed that most of the differentially expressed genes were upregulated and common gene signatures belonged to immune pathways (innate and adaptive), demonstrating a persistent low-grade immune response up to 4 weeks post-dosing. Interestingly and across all tissues considered, the impact of empty capsids or of the Promoterless vector was minimal, suggesting that the presence of the capsid and a productive viral genome causes the observed changes. This study provides unique insights into the transcriptional responses to AAV9 in key tissues primarily exposed by the vector.

Molecular Therapy — Methods & Clinical DevelopmentVol. 33(4)
Genomics Institute of the Novartis Research Foundation (US), Novartis (Switzerland) (CH), Novartis (China) (CN), Novartis (United States) (US)
Openalex Percentile: Top 68%
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.